| Literature DB >> 34657218 |
José A Bauermeister1, Ryan C Tingler2, Clara Dominguez3, Eileen F Dunne4,5, Craig Hoesley6, Ken Ho7, Sherri Johnson8, Jonathan Lucas8, Nicole Macagna8, Elizabeth Brown3, Holly Gundacker3, Melissa Peda3, Cindy E Jacobson9, Lindsay Kramzer9, Devika Singh9, Charlene S Dezzutti9,7, Ratiya Pamela Kunjara Na Ayudhya9, Mark A Marzinke10, Jeanna Piper11, Bríd Devlin12, Jeremy Nuttall12, Ian McGowan7, Craig W Hendrix9,10, Ross D Cranston13.
Abstract
This study describes the acceptability of a rectal microbicide gel formulation using dapivirine (DPV) among men and women from two countries (United States and Thailand) participating in the Microbicide Trials Network-026 trial. We evaluated participants' acceptability of a rectal DPV/placebo gel as part of a Phase I trial (N = 26; 18 male, 8 female). Participants reported favorable acceptability of the study gel, with most participants reporting that they liked the gel the same (n = 14; 53.8%) or more (n = 11; 42.4%) than when they started the trial. Over half of participants noted that they would prefer the gel over condoms (n = 13; 50%) or that they liked condoms and the gel equally (n = 8; 30.8%). Side effects across products included leakage (n = 8; 30.8%), diarrhea (n = 4; 15.4%), or soiling (n = 1; 3.8%). The high acceptability of a rectal gel underscores its promise as a short-acting biomedical prevention, warranting future research for HIV prevention.Trial Registration: NCT03239483.Entities:
Keywords: Dapivirine; HIV; HIV prevention; Microbicides; Rectal
Mesh：
Substances：
Year: 2021 PMID： 34657218 PMCID： PMC9024063 DOI： 10.1007/s10461-021-03490-8
Source DB: PubMed Journal: AIDS Behav ISSN： 1090-7165